|

JS105 Clinical Trials

2 actively recruiting trials

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Risen (Suzhou) Pharma Tech Co., Ltd.2

Indications

  • Cancer2
  • Advanced Solid Tumors1
  • Breast Cancer1

Other2 trials

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
Phase 1/2
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.